Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
NCT03478878Phase 1Completed
- Sponsor
- National Eye Institute
- Start
- May 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of retinyl palmitate in Reticular pseudodrusen (RPD) and age-related macular degeneration (AMD) (2 cohorts), sponsored by National Eye Institute. Primary endpoint: Dark Adaptation Rod Intercept Time at 2 months. Started May 2018; status: completed.
02
Drugs
retinyl palmitate
03
Conditions
Reticular pseudodrusen (RPD)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03478878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478878.